Abstract

Ihab Saeed Ahmed, Alaa Hussein Alwan, Mohanned H Alwan

Aim of study: To evaluate effect of infliximab therapy in Iraqi patients with ulcerative colitis and Crohn`s diseases.
Patients & Methods: A clinical prospective follow up study conducted in Gastroenterology and Hepatology Teaching Hospital-Medical Complex in Baghdad city-Iraq through the period from 1st of July 2013 to 30th of April 2014 on sample of 32 patients with inflammatory bowel disease (19 ulcerative colitis patients and 13 Crohn`s diseases patients). The patients were in active disease and not responding to usual treatment. The patients were administered with an appropriate dose of Infliximab.
Results: The good response to Infliximab was reported in 42.1% of UC patients, partial response in 21.1% of UC patients and no response in 36.8% of UC patients. Mean Mayo score of UC patients before using Infliximab was significantly reduced after using Infliximab (p<0.001). The good response to Infliximab was reported in 61.5% of CD patients, partial response in 15.4% of CD patients and no response in 23.1% of CD patients. Mean CDI score of CD patients before using Infliximab was significantly reduced after using Infliximab (p=0.001). The side effects were minor that restricted to anemia in some cases.
Conclusions: The Infliximab is effective and safe treatment choice for moderate to severe cases of ulcerative colitis and Crohn`s disease.